Browse investments

Invest in Hemab Therapeutics Holdings, Inc. on Stash

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.

To buy fractional shares of Hemab Therapeutics Holdings, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: COAG

Hemab Therapeutics Holdings, Inc.

$44.53

+41.41%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by LSEG Data & Analytics in partnership with: LSEG FX in collaboration with: LSEG Risk Intelligence. Stash cannot and does not represent or guarantee that any of the information available via LSEG Data & Analytics is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

COAG Performance Breakdown

Share Price

$44.53

Today's change

2.79%

Year to date change (YTD)

30.97%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About COAG

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.

Hemab Therapeutics Holdings, Inc. Stock Ticker

COAG

For more information

hemab.com

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by LSEG Data & Analytics in partnership with: LSEG FX in collaboration with: LSEG Risk Intelligence. Stash cannot and does not represent or guarantee that any of the information available via LSEG Data & Analytics is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Hemab Therapeutics Holdings, Inc. on Stash

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.

To buy fractional shares of Hemab Therapeutics Holdings, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Hemab Therapeutics Holdings, Inc. stock news

Business Insider

The leaders responsible for keeping OpenAI's AI safe keep leaving

OpenAI said its head of safety systems, Johannes Heidecke, has left. Heidecke is the latest in an ever-growing list of safety team leaders to quit the company.

4 days ago

24/7 Wall Street

Procter & Gamble vs PepsiCo: The Better Stock For Passive Income Investors

PepsiCo (NASDAQ: PEP | PEP Price Prediction) and Procter & Gamble (NYSE: PG) both just handed investors fresh earnings, and the businesses behind the tickers are steering in noticeably different directions.

4 days ago

CNBC

Elon Musk and Sam Altman spar on X after Apple files OpenAI lawsuit

A long-standing conflict between OpenAI CEO Sam Altman and SpaceX and Tesla CEO Elon Musk flared up again on X after Apple filed a lawsuit against OpenAI for alleged trade secret theft. Altman argued that Musk was obsessed with him because of a new OpenAI model release.

4 days ago

24/7 Wall Street

Goldman Sachs' Insane SpaceX AI Forecast Has One Clear Winner: Micron Technology

Artificial intelligence has already stretched the semiconductor supply chain to its limits.

4 days ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Hemab Therapeutics Holdings, Inc. stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Hemab Therapeutics Holdings, Inc.’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Hemab Therapeutics Holdings, Inc.’s price can fluctuate throughout the course of each trading day—when you buy Hemab Therapeutics Holdings, Inc. through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Hemab Therapeutics Holdings, Inc. stock price and the Hemab Therapeutics Holdings, Inc. news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers one subscription plan: The Stash Plan.

The Stash Plan can help you reach different goals and offers a unique combination of financial accounts and features. This plan includes access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Hemab Therapeutics Holdings, Inc. stock is complete, you'll officially be a shareholder of Hemab Therapeutics Holdings, Inc.!